Antibodies against glutathione S-transferase T1 in non-solid organ transplanted patients

BACKGROUND: This article describes the presence of antibodies against glutathione S‐transferase T1 (GSTT1) in a group of patients who never received a solid organ graft. These antibodies have been previously detected in liver and kidney transplant subjects with donor‐recipient mismatch for this enzy...

Full description

Saved in:
Bibliographic Details
Published inTransfusion (Philadelphia, Pa.) Vol. 46; no. 9; pp. 1505 - 1509
Main Authors Wichmann, Ingeborg, Aguilera, Isabel, Sousa, José M., Bernardos, Angel, García Núñez, Emilio J., Vigil, Eduardo, Magariño, Rosario, Magariño, Isabel, Torres, Antonia, Núñez-Roldán, Antonio
Format Journal Article
LanguageEnglish
Published Malden, USA Blackwell Publishing Inc 01.09.2006
Blackwell Publishing
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:BACKGROUND: This article describes the presence of antibodies against glutathione S‐transferase T1 (GSTT1) in a group of patients who never received a solid organ graft. These antibodies have been previously detected in liver and kidney transplant subjects with donor‐recipient mismatch for this enzyme at the genetic level. In liver‐grafted subjects, the appearance of these antibodies correlated with de novo immune hepatitis. STUDY DESIGN AND METHODS: To obtain some insights in this phenomenon, the clinical records of these patients were reviewed, and the possible causes leading to the production of these antibodies and possible clinical consequences were analyzed. RESULTS: The clinical situation of these patients was very heterogeneous, but they had in common the need for transfusions or a previous pregnancy. GSTT1 antigen is present in red blood cells, liver, kidney, and other tissues. Because the presence of the GSTT1‐null allele in seven of these patients has been demonstrated, it can be hypothesized that both GSTT1‐positive transfusions or pregnancy of a GSTT1‐positive fetus could induce these antibodies. Because the recipient is allele‐null, no adverse effects in the host are expected to occur. The longest follow‐up (5 years) shows no antibody‐derived diseases. CONCLUSION: It is concluded that anti‐GSTT1 can appear in a context different from the previously published alloreactivity after liver and kidney transplantation, as a consequence of transfusions and pregnancies. So far, no adverse clinical outcomes in our patients have been observed.
Bibliography:ark:/67375/WNG-VN8J1MMJ-N
ArticleID:TRF00938
istex:E0D18DE711380C89459B95C000339D4FDDE05394
This work has been supported by grants from Fondo de Investigaciones Sanitarias, Ministerio de Sanidad y Consumo, Spain: FIS 02/3072, FIS 05/0374 and Red Temática de Investigación en Trasplante C03/03.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0041-1132
1537-2995
DOI:10.1111/j.1537-2995.2006.00938.x